The prognostic impact of the tumour stroma fraction: A machine learning-based analysis in 16 human solid tumour types.

Journal: EBioMedicine
Published Date: Mar 1, 2021

Abstract

BACKGROUND: The development of a reactive tumour stroma is a hallmark of tumour progression and pronounced tumour stroma is generally considered to be associated with clinical aggressiveness. The variability between tumour types regarding stroma fraction, and its prognosis associations, have not been systematically analysed.

Authors

  • Patrick Micke
    Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala 751 85, Sweden.
  • Carina Strell
    Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala 751 85, Sweden.
  • Johanna Mattsson
    Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala 751 85, Sweden.
  • Alfonso Martín-Bernabé
    Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
  • Hans Brunnström
    Department of Clinical Sciences Lund, Division of Pathology, Lund University, Lund, Sweden; Department of Genetics and Pathology, Division of Laboratory Medicine, Region Skåne, Lund, Sweden.
  • Jutta Huvila
    Department of Pathology, University of British Columbia, Vancouver, Canada; Department of Pathology, University of Turku, Turku, Finland.
  • Malin Sund
    Department of Surgical and perioperative sciences/Surgery, Umeå University, Umeå, Sweden.
  • Fredrik Wärnberg
    Department of Surgery at Institute of Clinical Sciences, Sahlgrenska University Hospital Göteborg, Göteborg, Sweden.
  • Fredrik Ponten
    Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala 751 85, Sweden.
  • Bengt Glimelius
    Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala 751 85, Sweden.
  • Ina Hrynchyk
    City Clinical Pathologoanatomic Bureau, Minsk, Belarus.
  • Siarhei Mauchanski
    N.N. Alexandrov National Cancer Centre of Belarus, 223040 Minsk, Belarus.
  • Salome Khelashvili
    N.N. Alexandrov National Cancer Centre of Belarus, 223040 Minsk, Belarus.
  • Gemma Garcia-Vicién
    ProCURE, Program Against Cancer therapeutic Resistance, Catalan Institute of Oncology, Molecular Mechanisms and Experimental Therapy in Oncology Program (ONCOBELL), IDIBELL, L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.
  • David G Molleví
    ProCURE, Program Against Cancer therapeutic Resistance, Catalan Institute of Oncology, Molecular Mechanisms and Experimental Therapy in Oncology Program (ONCOBELL), IDIBELL, L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.
  • Per-Henrik Edqvist
    Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala 751 85, Sweden.
  • Aine O Reilly
    Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
  • Sara Corvigno
    Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala 751 85, Sweden; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
  • Hanna Dahlstrand
    Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala 751 85, Sweden; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
  • Johan Botling
    Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala 751 85, Sweden.
  • Ulrika Segersten
    Department of Surgical Sciences, Uppsala University, Uppsala 751 85, Sweden.
  • Agnieszka Krzyzanowska
    Department of Translational Medicine, Division of Urological Cancers, Lund University, Lund, Sweden.
  • Anders Bjartell
    Department of Urology, Skåne University Hospital, Lund University, Lund, Sweden.
  • Jacob Elebro
    Department of Clinical Sciences Lund, Division of Oncology and Therapeutic Pathology, Lund University, SE-221 00 Lund, Sweden.
  • Margareta Heby
    Department of Clinical Sciences Lund, Division of Oncology and Therapeutic Pathology, Lund University, SE-221 00 Lund, Sweden.
  • Sebastian Lundgren
    Department of Clinical Sciences Lund, Division of Oncology and Therapeutic Pathology, Lund University, SE-221 00 Lund, Sweden.
  • Charlotta Hedner
    Department of Clinical Sciences Lund, Division of Oncology and Therapeutic Pathology, Lund University, SE-221 00 Lund, Sweden.
  • David Borg
    Department of Clinical Sciences Lund, Division of Oncology and Therapeutic Pathology, Lund University, SE-221 00 Lund, Sweden.
  • Jenny Brändstedt
    Department of Clinical Sciences Lund, Division of Oncology and Therapeutic Pathology, Lund University, SE-221 00 Lund, Sweden.
  • Hanna Sartor
    Diagnostic Radiology, Department of Translational Medicine, Lund University, Skåne University Hospital, Lund, Sweden.
  • Per-Uno Malmström
    Department of Surgical Sciences, Uppsala University, Uppsala 751 85, Sweden.
  • Martin Johansson
    Department of Laboratory Medicine at Institute of Biomedicine, Sahlgrenska Universitety Hospital Göteborg, Göteborg, Sweden.
  • Björn Nodin
    Department of Clinical Sciences Lund, Division of Oncology and Therapeutic Pathology, Lund University, SE-221 00 Lund, Sweden.
  • Max Backman
    Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala 751 85, Sweden.
  • Cecilia Lindskog
    Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.
  • Karin Jirström
    Department of Genetics and Pathology, Division of Laboratory Medicine, Region Skåne, Lund, Sweden; Department of Clinical Sciences Lund, Division of Oncology and Therapeutic Pathology, Lund University, SE-221 00 Lund, Sweden.
  • Artur Mezheyeuski
    Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala 751 85, Sweden. Electronic address: artur.mezheyeuski@igp.uu.se.

Keywords

External Resources

Popular Topics
Recent Journals